Press release
Creative Diagnostics Introduces the Launch of Beta Actin Antibody
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently expanded antibody portfolio with the launch of a series of beta actin antibody for ICC/IF, WB, and IHC-P. These new products are only for research use, and are not intended for diagnostic use.Creative Diagnostics offers primary antibodies to multiple forms of virtually every protein in the proteome, and secondary antibodies that are available targeting all common research species and are conjugated with multiple types of enzymes and fluorescence, as well as control antibodies to make sure researchers generating data with confidence. Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. The anti beta actin monoclonal antibodies can be used to detect beta-actin, which is one of six different actin proteins.
For example, Anti-ACTB monoclonal antibody (DCABH-10282), one of the products included in this release, is mouse anti-Human ACTB monoclonal antibody that can be used for ICC/IF, WB, and IHC-P. This antibody can specifically recognize beta actin in tissues or species through immunoblotting, immunofluorescence staining of cultured cell lines, and immunohistochemistry.
"Creative Diagnostics is committed to developing and delivering high quality research tools and solutions to the life science community, and we're so glad to advance our clients' scientific discoveries and accelerate their next breakthrough by continuously offering such monoclonal antibodies. Our mouse monoclonal antibody to beta actin is now available for global researchers, and more improved antibodies and services will be offered to meet the unmet needs of scientists working in basic research and development." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.
"Creative diagnostics offers a wide range of high quality antibodies validated for use in multiplexed assays. Beta actin antibodies are highly complementary to our existing antibody offerings and will further help us meet the continuing demands from our customers for high quality antibodies. We'll continue to work to develop more antibody products and customized services for researchers in the future." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.
If you want to know more information about beta actin antibodies or other research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com/.
NY 11967, USA
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Creative Diagnostics Introduces the Launch of Beta Actin Antibody here
News-ID: 2251851 • Views: …
More Releases from Creative Diagnostics
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facili …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal antibodies, Anti-Fluorescien monoclonal antibodies, and Anti-FAM polyclonal antibodies.
Traditional nucleic acid detection methods require trained operators and sophisticated…
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Resear …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced a series of new ELISA Kits to assist researchers in studing the mechanisms of autoimmunity, including those associated with anti-neotrophil, anti-nuclear, rheumatic diseases, endocrine autoantibodies, and the neurological system.
The immune system has very powerful effector mechanisms to destroy a wide range of pathogens. Early in the study of immunity, it was recognized that if these…
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of new reagent solutions for herpesvirus research, including a range of Human Herpesviruses Antibodies designed to help researchers better understand the structure of Herpesvirus entry and develop new treatments and prevention strategies.
The Herpesviridae are a large family of double-stranded DNA enveloped viruses that cause a variety of diseases. The nine human herpesviruses are…
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 fo …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, has launched a set of highly specific antibodies against FXIIIa/F13A1 for vascular diseases. These antibodies can be used in various scientific applications such as WB, ELISA, IHC, and IP to facilitate drug development research.
Coagulation Factor XIIIa (FXIIIa) is a plasma transglutaminase that catalyzes the final step of the coagulation process and plays an important role in hemostasis.…
More Releases for R&D
Siveco doubles China R&D investment
On July 3, 2019, Siveco China held its half-year management meeting at the prestigious Hellas House in Shanghai, a nod to the company's continuing growth on the Belt & Road. With financial results above target, high customer satisfaction (as shown in the latest audited customer satisfaction survey) and a sales pipeline more promising than ever, the company's management board announced that shareholders have approved its request for additional investment in…
R&D Collaborative Projects by GD Rectifiers
GD Rectifiers have extensive experience in collaborative R&D projects and are proud to work with some of the UK’s pioneering power electronic companies to drive design and innovation forward.
This R&D service helps drive GD Rectifiers forward as a cutting edge manufacturer embracing fundamental technologies that support product development that contribute to next generation products throughout: renewable energy, embedded systems, smart metrering and the rail industry.
Power Assemblies, Controllers and…
Transforming Pharmaceutical R&D with Data
ReportsWorldwide has announced the addition of a new report title Transforming Pharmaceutical R&D with Data to its growing collection of premium market research reports.
Transforming Pharmaceutical R&D with Data
In the current drug pricing environment, biopharmaceutical firms cannot afford to continue spending billions of dollars on development programs that are more than 90% likely to fail. Raising prices to compensate for expensive, risky research and development (R&D) is no longer an option…
Noliac is expanding the R&D team
Noliac is looking for two new colleagues for the R&D team in Prague, Czech Republic: A Precision/Fine Mechanics and an Electroengineer.
Precision/Fine Mechanics
For the R&D team in Prague, Czech Republic, Noliac is looking for a Precision/Fine mechanics to work on modifying existing products and work with developing new. Noliac requires a colleague who:
Is mechanically skilled with a focus on very small machinery.
Holds a technical high school degree or an apprenticeship…
Leiber GmbH further invests in R&D
Since February 2016, Leiber GmbH has been reinforced by Dr med vet Claudia Westfahl - a veterinarian specialized in animal nutrition - as part of the company's strategy to invest in new product developments. With the new position ‘Product Development Animal Nutrition’, Dr Westfahl is responsible for new product development in the field of functional feed ingredients for both pet as well as farm animals. After graduating at the University…
Rising R&D Funding for Nanotechnology
Global nanotechnology market has been registering marked increase in funds allocation by the countries across the world, especially with new product development that received huge momentum due to these funding. An increase in global public funding for R&D initiatives supports quick commercialization of nano-based products. Fundings from governments, corporations, and venture capital exhibited a CAGR growth of 1% during 2008-2012. In future, it is expected that nanotechnology funding will grow…
